Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Dec 15, 2014 7:02am EST

Second Part of the Glaucoma Phase II study has been Approved in a European Country

Dec 09, 2014 7:00am EST

Can-Fite to Initiate the Development Program of its Next Generation Drug CF602

Dec 02, 2014 5:49pm EST

Can-Fite Announces $8 Million At-The-Market Registered Direct Offering

Dec 01, 2014 7:00am EST

US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101

Dec 01, 2014 7:00am EST

Can-Fite Reports Financial Results for Nine Months Ended September 30, 2014

Nov 18, 2014 7:00am EST

Can-Fite Near-Term Milestones Timetable for 2014/2015

Nov 17, 2014 5:48pm EST

Can-Fite Announces Special General Meeting of Shareholders to Elect External Director

Nov 13, 2014 7:00am EST

Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting

Oct 30, 2014 7:00am EDT

Can-Fite to Participate in BIO-Europe International Partnering Conference

Oct 07, 2014 7:00am EDT

Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session

  • arrow_back
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding